Startups
Accure Therapeutics is a R&D pharma company dedicated to developing innovative medicines to treat patients suffering from Central nervous system (CNS) diseases, a major medical challenge.
Overview
Total raised
$9.97M
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 5, 2025 | Asabys Partners | asabys.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| May 27, 2020 | Series A round | $8.37M |
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 7, 2025 | Accure Therapeutics secures $1.6M from Michael J. Fox Foundation and Luxembourg national research Fund | Barcelona neuroscience R&D company Accure Therapeutics has received two grants totalling €1.46 million for two separate development programs on its drug candidate ACT-02. ACT-02 is a novel asset with disease-modifying potential, inhibit... |
| May 16, 2024 | Accure Therapeutics awarded €1 million from Spanish government to evaluate ACT-03 for post-traumatic epilepsy | Read the full press release here: https://accure.health/accure-therapeutics-awarded-e1-million-from-spanish-government-to-evaluate-act-03-for-post-traumatic-epilepsy/ |
| Mar 6, 2024 | Which are Barcelona’s Most Influential Biotechnology Startups in 2023? | Barcelona, the cosmopolitan capital of Spain’s Catalonia region, is famed not only for its art and architecture but also for its bustling biotechnology startup scene. Catalonian biotech startups have been turning heads globally thanks to th... |
| Jan 24, 2024 | Who are Catalonia’s Most Influential Game-Changers in Biotech, 2023? | The biotechnology scene in Catalonia, Spain, is thriving, with many innovative start-ups to its credit. Each of these companies is working towards the monumental task of pushing the boundaries of science to shape the future of healthcare, l... |
| Mar 3, 2022 | Oculis in-licenses neuroprotective drug candidate for glaucoma | |
| Mar 2, 2022 | Oculis Strengthens Leading Ophthalmology Pipeline by InLicensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics | Lausanne, Switzerland, and Barcelona, Spain, March 2, 2022 – Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics,... |
| Mar 2, 2021 | Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01 | https://accure.health/accure-therapeutics-enrols-first-patient-in-phase-ii-clinical-trial-on-acute-optic-neuritis-with-lead-candidate-act-01/ |
| Feb 12, 2021 | Accure Therapeutics publishes pivotal preclinical efficacy study in epilepsy | https://accure.health/accure-therapeutics-publishes-pivotal-preclinical-efficacy-study-in-epilepsy/ |
| Feb 10, 2021 | Accure Therapeutics – Webinars on Neuroprotection for Brain Diseases Program | https://accure.health/webinars-on-neuroprotection-for-brain-diseases-program/ |
Show more
Reviews 0
FAQ about Accure Therapeutics
How much funding has Accure Therapeutics raised?
Accure Therapeutics has raised $9.97M in total across 2 funding rounds.
What funding rounds has Accure Therapeutics raised?
Parsers VC lists 2 funding rounds of Accure Therapeutics, among them a Series A round of $8.37M on May 27, 2020.
Who has invested in Accure Therapeutics?
Parsers VC lists 2 investors of Accure Therapeutics, among them Asabys Partners.
What has the press written about Accure Therapeutics?
Parsers VC has collected 14 articles mentioning Accure Therapeutics, among them “Accure Therapeutics secures $1.6M from Michael J. Fox Foundation and Luxembourg national research Fund” (Apr 7, 2025) and “Accure Therapeutics awarded €1 million from Spanish government to evaluate ACT-03 for post-traumatic epilepsy” (May 16, 2024).
Is Accure Therapeutics still active?
Yes, Accure Therapeutics is active; its latest activity on Parsers VC dates from Nov 5, 2025.